calmangafodipir
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01619423)
Timeline
Indications
Mechanism of action
- Superoxide dismutaseACTIVATOR
SOD1 activator
Chemistry & pharmacology
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297714 ↗
Also known as
- pledox
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04034355 | Phase 3 | Nov 1, 2018 | PledPharma AB, Solasia Pharma K.K., University of California, San Francisco |
| NCT03654729 | Phase 3 | Oct 31, 2018 | PledPharma AB |
| NCT01619423 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | Pharma Consulting Group AB, PledPharma AB |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PledPharma AB | For profit | 3 | 3 | 2 | 2012 |
| Pharma Consulting Group AB | For profit | 1 | 0 | 1 | 2012 |
| Solasia Pharma K.K. | For profit | 1 | 0 | 1 | 2018 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1